Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Q4 2021 Earnings Presentation
38 slides from Neurocrine Biosciences's earnings presentation, Feb 11, 2022
Slide 1: Q4 2021 / Year-End Corporate Presentation
Advancing Life-Changing Discoveries in Neuroscience Q4 2021 / Year-End Corporate Presentation February 11, 2022 Nasdaq: NBIX
Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures
Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our
Slide 3: Well Positioned for Sustained & Long-term Growth
Well Positioned for Sustained & Long-term Growth ~450,000 * Exceeded Annual Sales undiagnosed and untreated patients of ~$1B in 2021 with TD in the U.S. (Less than 5 Years Since Launch) Significant Opportunity for Growth 12 Programs Currently in R&D Focus Robust Mid-to-Late-Stage Studies • Neurology
Slide 4: Q4 & FY 2021 Highlights and Future Key Milestones & Activities
Q4 & FY 2021 Highlights and Future Key Milestones & Activities Q4 2021 & FY Highlights Future Key Milestones & Activities ▪ INGREZZA® (valbenazine) Net Product Sales of ~$1.1 Billion ▪ Continued INGREZZA Commercial Execution with 200,000 TRx in 2021 − Complete Salesforce Expansion by End of Q1 2022
Slide 5: Strong Pipeline Momentum
Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Tardive Dyskinesia (MTPC) Approval in Japan Expected in 2022 Supplemental New Drug Application (sNDA) valbenazine* Chorea in Huntington Disease Filing in 2H 2022 valbenazine* Dyskinetic Cerebral Palsy
Slide 6: Pipeline Features Novel Mechanisms to Treat Intractable Diseases
Pipeline Features Novel Mechanisms to Treat Intractable Diseases Focused on Neurology, Neuroendocrinology, and Neuropsychiatry Neurology Neuroendocrinology Epileptic SCN8A Encephalopathy Focal Onset Developmental Tardive Essential with Continuous Seizures (FOS) and Epileptic Endometriosis Dyskinesia
Slide 7: Significant Clinical Progress Expected Over the Next Two Years
Significant Clinical Progress Expected Over the Next Two Years Significant Milestones This Year 2023 Clinical Activities & Milestones Valbenazine in Chorea in Huntington Disease Crinecerfont for CAH in Adults sNDA Filing Registrational Top-line Data NBI-827104 in EE-CSWS Crinecerfont for CAH in Chil
Slide 8: Significant Milestones This Year
Significant Milestones This Year Valbenazine* NBI-827104** NBI-827104** Chorea in HD Essential Tremor EE-CSWS sNDA filing in 2H 2022 Phase 2 data in Mid-2022 Phase 2 data in 2H 2022 T-type calcium channel blocker T-type calcium channel blocker VMAT2 inhibitor (Cav 3.1, Cav 3.2, Cav 3.3) (Cav 3.1, Ca
Slide 9: 2021 Annual Financial Summary
2021 Annual Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item 2021 2020 Highlights / Comments Revenue $1,133 $1,046 - Product Sales, Net 1,090 994 INGREZZA Sales of ~$1.1 Billion - Collaboration Revenue 43 52 YoY Increase Driven by Expanded / Advancing Non-GAAP R&D Expense 280 24
Slide 10: Q4 2021 Financial Summary
Q4 2021 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q4 2021 Q4 2020 Highlights / Comments Revenue $312 $248 INGREZZA YoY Sales and TRx Grew 25% and 32%, - Product Sales, Net 304 241 Respectively - Collaboration Revenue 8 7 Increase to Support Expanded / Advancing Portfolio,
Slide 11: 2022 INGREZZA Sales and Operating Expense Guidance
2022 INGREZZA Sales and Operating Expense Guidance Item ($ Millions) 2021 Actuals 2022 Guidance Range INGREZZA Net Product Sales1 $1,082 $1,250 - $1,350 GAAP R&D Expense2 $328 $410 - $430 Non-GAAP R&D Expense3 $280 $350 - $370 GAAP SG&A Expense4 $583 $690 - $720 Non-GAAP SG&A Expense3 $498 $580 - $6
Slide 12: Our Medicines, Our Patients
Our Medicines, Our Patients Q4 2021 and Full-Year Earnings Presentation
Slide 13: INGREZZA Quarterly Net Sales Performance
INGREZZA Quarterly Net Sales Performance ($MM) $320 3rd Sequential Quarter of Growth in Covid-Era $301 $300 $287 $280 $268 $265 $260 $254 $240 $240 $231 $230 $220 $200 Q1 '20 Q2 '20 Q3 '20 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 13
Slide 14: Substantial Impact on TD Patients and Caregivers
Substantial Impact on TD Patients and Caregivers Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Worth
Slide 15: Nascent TD Market Presents Significant Opportunity
Nascent TD Market Presents Significant Opportunity ~25% E S T I M AT E D T O A F F E C T ~600,000 people in the U.S. patients with TD diagnosed Increasing Antipsychotic Prescriptions (U.S.) ~75 % 19.0 3% Compound Annual TRx (Millions) Growth Rate from 2017 - 2021 18.0 17.0 market is not yet diagnose
Slide 16: Driving Long-Term Growth for INGREZZA
Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach
Slide 17: Filing sNDA for Valbenazine for Chorea in Huntington Disease in 2H 2022
Filing Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease in 2H 2022 Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Promising safety profile supported by extensive safety data in tardive dyskinesia In randomi
Slide 18: Valbenazine: Registrational Programs in ATS and DCP
Valbenazine*: Registrational Programs in ATS and DCP with Top-Line Data Expected for Both Programs in 2023 Adjunctive Treatment of Schizophrenia (ATS) Dyskinetic Cerebral Palsy (DCP) Schizophrenia is one of the leading causes A form of cerebral palsy (CP) that affects of disability worldwide, affect
Slide 19: ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor
ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson’s Disease Provides Significant Reduction of Daily “Off” Time; Increase in Good “On” Time • Add-on treatment to levodopa/carbidopa prolongs clinical effects • One capsule, once a day treatment • Helps patients achieve m
Slide 20: Classic Congenital Adrenal Hyperplasia (CAH)
Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder • Enzyme deficiency • Reduced cortisol U.S. Europe levels and excess ~30,000* ~50,000* androgen levels Complex and Highly Treatment Options Variable Stagnant for 60 Years Symptoms • Hormone replacement • Do not address underlying iss
Slide 21: Congenital Adrenal Hyperplasia Disease Mechanism
Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 21
Slide 22: Crinecerfont Potentially Meets Challenges of the Standard of Care
Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT
Slide 23: Potential Paradigm Shift in the Treatment of CAH
Potential Paradigm Shift in the Treatment of CAH Crinecerfont* Phase 3 Global Registrational Study in Adults Ongoing Top-Line Results Phase 3 Pediatric Registrational Study Ongoing Expected in 2023 Potent Orally Active Selective Well-Tolerated *Crinecerfont is investigational and not approved in any
Slide 24: Potential First-in-Class Neuropsychiatry Programs: Takeda Collaborations
Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies Cognitive Impairment Associated Luvadaxistat* Ongoing Phase 2 Study with Schizophrenia (CIAS) Inadequate Response to Treatment in NBI-1065845 Majo
Slide 25: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor
Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor million people in the U.S. diagnosed • Once daily with schizophrenia • No titration requirement Hypofu
Slide 26: Potential First-in-Class Neuropsychiatry Programs: Idorsia and Xenon
Potential First-in-Class Neuropsychiatry Programs Collaborations with Idorsia and Xenon Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies Essential Tremor Top-line Data Expected in Mid-2022 NBI-827104* Rare Pediatric Epilepsy: EE-CSWS Top-line Data Expected in 2H 2022
Slide 27: NBI-827104: Selective Cav Blocker
NBI-827104*: Selective Cav Blocker NBI-827104 Investigational, potent, selective, orally active and brain penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) with 1x/day dosing Program has potential to address other central nervous system diseases Essential Tremor Program EE-CSWS
Slide 28: NBI-827104: Enrolling Patients in Phase 2 Studies
NBI-827104*: Enrolling Patients in Phase 2 Studies Essential Tremor Background EE-CSWS Background Essential tremor is one of the most common Rare pediatric epilepsy characterized by onset movement disorders, affecting an estimated seizures between 2 and 12 years of age. 10 million people in the U.S.
Slide 29: NBI-921352: Selective Nav 1.6 Inhibitor
NBI-921352*: Selective Nav 1.6 Inhibitor NBI-921352 Potent, highly selective Nav1.6 inhibitor to precisely target the sodium channel affected by the genetic mutation of SCN8A Program has potential to address other central nervous system diseases Adult Focal Onset Seizures Program SCN8A-DEE Program P
Slide 30: NBI-921352: Ongoing Phase 2 Studies
NBI-921352*: Ongoing Phase 2 Studies Adult Focal Onset Seizures Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the most common form of seizures seizures beginning in the first 18 months of in adults, impacting ~1.8 mil
Slide 31: Novel Muscarinic Receptor Agonists Collaboration with Sosei Heptares
Novel Muscarinic Receptor Agonists Collaboration with Sosei Heptares Neurocrine Biosciences Initiating Clinical Studies for Muscarinic Portfolio Initiating clinical studies, including: ➢ Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 orthosteric agonist, as a potential treatment fo
Slide 32: Well Positioned for Sustained & Long-term Growth
Well Positioned for Sustained & Long-term Growth ~450,000 * Exceeded Annual Sales undiagnosed and untreated patients of ~$1B in 2021 with TD in the U.S. (Less than 5 Years Since Launch) Significant Opportunity for Growth 12 Programs Currently in R&D Focus Robust Mid-to-Late-Stage Studies • Neurology
Slide 33: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations neurocrine.com
Slide 34: Condensed Consolidated Statements of (Loss) Income
NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME (unaudited) (in millions, except per share data) Revenues: Product sales, net Collaboration revenue Total revenues Operating expenses: Cost of sales Research and development Acquired in-process res
Slide 35: Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) NEUROCRINE BIOSCIENCES, INC. (unaudited) Cash, cash equivalents and debt securities available-for-sale Other current assets Total current assets Deferred tax assets Debt securities available-for-sale Right-of-use assets Equity securities Property a
Slide 36: Reconciliation of GAAP to Non-GAAP Financial Results
NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, (in millions, except per share data) 2021 2020 2021 2020 GAAP net (loss) income $ 3) $8 3479 $ 896 $ 4073 Adjustments:
Slide 37: Reconciliation of GAAP to Non-GAAP Expenses
NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) Three Months Ended ‘Twelve Months Ended December 31, December 31, (in millions) 2021 2020 2021 2020 GAAP R&D $ 874 $ 66.7 $ 328.1 $ 275.0 Adjustments: Share-based compensation expense 12.2 73 48.4 33.7 Non-GAAP R&D
Slide 38: Advancing Life-Changing Discoveries in Neuroscience
Advancing Life-Changing Discoveries in Neuroscience Q4 2021 / Year-End Corporate Presentation February 11, 2022 Nasdaq: NBIX
Neurocrine Biosciences — Q4 2021 Earnings Presentation on 6ix